Silverback Therapeutics (SBTX) Stock Chart & Stock Price History $13.51 +0.01 (+0.07%) As of 08/25/2025 Add Compare Share Share Chart Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrendsBuy This Stock Silverback Therapeutics Stock Price Performance The Silverback Therapeutics (SBTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 2.35%, with a year-to-date return of 27.21%. In the past month, the stock has decreased 24.61%, reflecting recent market activity. As of the latest close, Silverback Therapeutics traded at $13.50 with a market cap of $486.78 million and volume of 3.13 million shares. Receive SBTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-7.47%1 Month Performance-24.61%3 Month Performance-9.81%Year-To-Date Performance+27.21%1 Year Performance+2.35% SBTX Stock Chart for Tuesday, August, 26, 2025 SBTX Chart by TradingView Silverback Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/25/2025$13.50$13.50$14.97$13.463.13 million shs$486.78 million08/22/2025$14.60$14.87+1.85%$15.09$14.301.52 million shs$536.18 million08/21/2025$13.79$14.60+5.87%$14.74$13.652.16 million shs$526.45 million08/20/2025$14.03$13.79-1.71%$14.13$13.512.18 million shs$497.24 million08/19/2025$14.53$14.03-3.44%$14.62$14.011.67 million shs$505.89 million08/18/2025$14.53$14.53$14.91$14.262.89 million shs$523.92 million08/15/2025$15.82$14.47-8.53%$15.72$14.313.42 million shs$521.76 million08/14/2025$16.66$15.82-5.04%$16.65$14.504.31 million shs$570.44 million08/13/2025$16.38$16.66+1.71%$17.46$16.102.08 million shs$600.73 million08/12/2025$17.50$16.38-6.40%$17.54$15.902.29 million shs$590.63 million Get the Latest News and Ratings for SBTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 08/11/2025$17.50$17.50$17.90$17.40715,589 shs$631.02 million08/08/2025$17.98$17.65-1.84%$18.00$17.34741,288 shs$636.42 million08/07/2025$17.80$17.98+1.01%$18.00$17.391.03 million shs$648.32 million08/06/2025$17.38$17.80+2.42%$18.00$17.23942,957 shs$641.83 million08/05/2025$17.18$17.38+1.16%$17.62$17.081.20 million shs$626.69 million08/04/2025$17.18$17.18$17.70$17.071.18 million shs$619.48 million08/01/2025$17.88$17.68-1.12%$17.91$17.511.09 million shs$211.66 million07/31/2025$17.75$17.88+0.73%$18.42$17.731.11 million shs$644.72 million07/30/2025$18.35$17.75-3.27%$18.50$17.70728,720 shs$640.03 million07/29/2025$17.87$18.35+2.69%$18.63$17.782.06 million shs$211.66 million07/28/2025$17.87$17.87$18.05$17.412.73 million shs$644.36 million07/25/2025$18.00$17.92-0.44%$18.16$17.701.29 million shs$646.16 million Related Companies CALT Stock Price Chart ZYME Stock Price Chart MBX Stock Price Chart AVTE Stock Price Chart NLTX Stock Price Chart BIOA Stock Price Chart CYBN Stock Price Chart VIRI Stock Price Chart WHWK Stock Price Chart OSTX Stock Price Chart Receive SBTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SBTX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silverback Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Silverback Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access